Loading patent…
OwnerClifford Stanners, Christian Ilantzis +1inventors
InventorsClifford Stanners, Christian Ilantzis, Cosme Ordonez-Garcia
Estimating the term…
The present invention relates to differentiation, apoptosis and tumorigenicity. The present invention more particularly relates to compositions comprising ligands which target CEA such that the adhesion, differentiation-Inhibitory and apoptosis-resistance activities (tumorigenic effects) of Ig superfamily member, CEA, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents comprising compositions which reverse the CEA-mediated tumorigenic effects and enable a lowering of the doses of a chemotherapeutic agent. In one embodiment the invention relates to methods of reducing, preventing or reversing CEA-mediated tumorigenic effects comprising a use of an amount of a CEA declustering agent comprising compositions that can reverse a CEA mediated tumorigenic effect. In one embodiment, the invention further relates to compositions comprising a CEA declustering agent for reversing CEA-mediated tumorigenic effects and restoring drug induced apoptosis to human cancer cells and uses thereof.
A composition for reversing a CEA-mediated tumorigenic effect comprising a CEA-declustering agent and a cytotoxic agent, together with a pharmaceutically acceptable carrier.
(canceled)
Use of a monovalent CEA binding agent together with a cytotoxic drug to reduce, prevent or reverse a CEA-mediated tumorigenic effect, comprising an administration of an effective amount of said monovalent CEA declustering agent and cytotoxic drug, together with a pharmaceutical carrier.
Dependencies are inferred from the claim text.